Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Manufacturer Direct-to-Patient (Cash-Pay) Programs Both Novo Nordisk and Eli Lilly have launched direct-to-patient platforms offering GLP-1 medications at flat cash-pay rates significantly below the insurance list price
Within the Strand Bio GLP category, Semaglutide can be compared with Tirzepatide, Retatrutide, and Cagrilintide using shared record fields
Retatrutide is a 39-amino-acid synthetic triple-receptor agonist peptide that activates GLP-1, GIP, and glucagon receptors simultaneously
The turnaround wasn't bad its admittedly better than some companies weve dealt with over the years but it was significantly slower than the other brands in this guide
US$ 28.79
US$ 26.09
US$ 23.70
